淄博这家“小巨人”企业更换券商后，火速重启上市

Core Viewpoint - The company, Haos, is moving forward with its plan to publicly issue stocks and list on the Beijing Stock Exchange after changing its advisory broker and terminating its previous listing plan on the Shenzhen Stock Exchange [2][4]. Group 1: Company Overview - Haos Biotechnology Co., Ltd. was established in December 2015, with a registered capital of 71.2 million yuan, located in Hantai County, Zibo City [2]. - The company specializes in the research, production, and sales of collagen sausage casings and is recognized as a national-level "little giant" enterprise, a national high-tech enterprise, and a Shandong Province gazelle enterprise [2]. Group 2: Financial Performance - In 2024, Haos reported an operating income of 423.49 million yuan, a year-on-year decrease of 5.60%, and a net profit attributable to shareholders of 109.77 million yuan, down 4.33% [4]. - For the first half of 2025, the company achieved an operating income of 200.75 million yuan, a decline of 1.21%, with a net profit of 45.74 million yuan, down 17.59% [4]. - The revenue growth is heavily reliant on a single product, with collagen sausage casings accounting for 99.71% of the total revenue in the first half of 2025 [4]. Group 3: Listing Plans - Haos has signed a new advisory agreement with China Merchants Securities on December 15, 2025, and submitted the necessary materials for listing on the Beijing Stock Exchange [2]. - The company must be listed for at least 12 months before it can publicly issue stocks to unspecified qualified investors on the Beijing Stock Exchange [5].